Bayer braces for looming Trasylol review

The atmosphere could be contentious when Bayer's Trasylol comes before an FDA advisory committee Wednesday. FDA documents posted in advance of the meeting state that the agency's statisticians concluded that the drug--used to control bleeding during heart surgery--may increase risk of kidney failure and death (a.k.a. "mortality disadvantage").

That the committee is discussing Trasylol again is in itself a story. The company withheld data about possible risks of the drug from the FDA last year; two employees have been suspended because of it.

- read the FDA's briefing report

Related Articles:
Investigator: Bayer did not hide Trasylol data. Report
Bayer kept Trasylol safety study hidden from FDA. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.